Simplify Asset Management’s Pacira BioSciences PCRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$2.07M Sell
82,814
-269
-0.3% -$6.81K 0.03% 57
2026
Q2
$2.11M Buy
83,083
+20,430
+33% +$483K 0.03% 59
2026
Q1
$1.42M Sell
62,653
-23,608
-27% -$525K 0.02% 65
2025
Q4
$2.23M Buy
86,261
+41,315
+92% +$982K 0.04% 61
2025
Q3
$1.16M Sell
44,946
-75,897
-63% -$1.86M 0.02% 77
2025
Q2
$2.89M Sell
120,843
-13,199
-10% -$333K 0.15% 34
2025
Q1
$3.33M Buy
134,042
+96,300
+255% +$2.31M 0.12% 32
2024
Q4
$711K Buy
+37,742
New +$663K 0.04% 73

Other funds holding PCRX

Simplify Asset Management's PCRX Position: Q3 2026 in Review

Simplify Asset Management reduced its Pacira BioSciences (PCRX) stake by 0.32% in Q3 2026, selling an estimated $6.81K and leaving 82,814 shares worth $2.07M. The position accounts for 0.03% of the portfolio, ranked #57.

Simplify Asset Management first reported a position in PCRX in Q4 2024 and has held it in 8 quarters since. The position peaked at $3.33M in Q1 2025. 258 funds tracked by Wall St. Rank hold PCRX as of Q3 2026.

  • Simplify Asset Management held 82,814 shares of Pacira BioSciences worth $2.07M as of Q3 2026.
  • Simplify Asset Management sold 269 Pacira BioSciences shares in Q3 2026, an estimated $6.81K.
  • Pacira BioSciences made up 0.03% of Simplify Asset Management's portfolio in Q3 2026, its #57 holding.
  • Simplify Asset Management first reported a position in Pacira BioSciences in Q4 2024 and has held it in 8 quarters since.
  • Simplify Asset Management's Pacira BioSciences position peaked at $3.33M in Q1 2025.
  • 258 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2026.

Based on Simplify Asset Management's 13F filing for Q3 2026, filed 27 Oct 2026.